GYN Conferences 2024 Midyear Highlights

CME

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: July 25, 2024

Expiration: January 24, 2025

Floor J Backes
Floor J Backes, MD
Angeles Alvarez Secord
Angeles Alvarez Secord, MD, MHSc

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your patient has a history of high-risk serous endometrial cancer. She presents with new lung metastases, and biopsy reveals recurrent endometrial cancer with a P53 mutation; her tumor is HER2 low (inconclusive) and has mismatch repair deficient status by immunohistochemistry testing.

What treatment would you recommend for this patient at this time?